Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
about
Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesLung Cancer Gene Signatures and Clinical PerspectivesKinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicineMolecular pathways and therapeutic targets in lung cancerNew developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?Prognostic markers in lung cancer: is it ready for prime time?Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre.Use of ChemoFx® for Identification of Effective Treatments in Epithelial Ovarian CancerErlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trialsHepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastasesThe comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusHistorical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Proteomic biomarkers in lung cancer.Molecular pathology in lung cancer: a guide to the techniques used in clinical practice.The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.Mass spectrometry protein tests: ready for prime time (or not).Lung Cancer Staging and Prognosis.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays.Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer.A new proteomic test could guide treatment decision in second-line therapy for patients with EGFR unselected non-small cell lung cancer?The value of proteomics in lung cancer.Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR.Blood-based biomarkers in lung cancer: prognosis and treatment decisions.Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
P2860
Q26798882-5F8C73C5-8B77-4CEE-B810-27D92312B9DDQ27014117-C5F52798-43CB-4066-B74D-22982B970445Q28387769-AD4B0225-977D-449C-86F2-55506CCD79A7Q28542940-D3C3CBC9-A213-4D9E-A608-10B7B2E0FE79Q33688872-70B9A3C1-5BAB-400B-921F-4C09D98AC3AAQ33704088-E8F43DB3-55E8-4D87-809F-6AFDD2A411B4Q33778668-E96564AC-DB76-469F-9283-6B7EC8C71046Q33913549-1F434328-29B3-43A6-985C-9CD831762440Q35034044-A1E15639-605F-4735-B8A9-3B8DABEB59F0Q35169166-A02EB894-F150-4491-B23B-BF79E1A98BB3Q35200555-B4A0831B-F1EB-4515-BCAB-24B148992719Q35238008-CC35D87C-C750-4354-80D9-2FFD3A28C8BAQ35714621-5A057FCA-61B4-48C7-8D80-519F09E73ACFQ35715271-2EF1612C-71E0-474B-8380-564AD0249327Q35996048-3CE26633-63BE-4A34-B19F-AC1BA6FD3E22Q36525517-177DB3A5-B5D7-4E84-8C26-A325E5982E80Q36642739-3C53BBDA-C01D-46D4-BE5D-062161DEA4A8Q36833970-A83F4817-A879-499C-8783-A6A787493B1CQ37392573-B2615845-0319-4DE4-9AF4-125D342AC42CQ37598057-F761BFE2-9476-4AA0-B450-7AC276926CADQ38100750-63FA59FE-C723-4AFA-99E5-C93922FCDB7BQ38240593-C6C0AD41-801B-41BF-A155-6376641EFF03Q38768030-48773CE0-4CF8-48EA-B1B2-4BFDA9E53081Q38799731-0F18756E-0913-4150-A46A-33A984EC3E64Q38830349-3C908A7A-3A3F-4421-923C-BA5716EE6E50Q38844281-98BE8169-A9D7-42A0-913B-8D5107BC9439Q38982951-39C35928-C6C3-4050-9E77-53E018FF71EEQ38987067-7369E82D-50F7-4A9C-A202-ECD1588032E8Q40451221-D707F947-9162-4A48-AAE8-45C413DE7BF1Q40733332-35EECE09-2AD3-406F-A8B3-0552D71D2831Q41670014-B42B2175-0414-4AA5-9DD1-5BB12B983E4FQ41814784-B43CB5CB-67B8-4D6B-A581-1E39ECF2FCC1Q42181353-4C2CD7CB-0E30-4112-8661-EB009CF47060Q43183700-DF1A7CD2-C21A-4B4C-ABB2-8128885DF040Q46603973-3A46C196-600C-4C0F-9D01-3342C9CD57FBQ47116389-34F414B6-949E-4628-85F5-E334150BA31EQ51104457-40E91EAB-9F45-4E11-ADD2-3BE92C485D39Q51136000-5ED664A2-F930-426B-ABD4-A7AF18933EF1Q52646495-06594BF1-5EFC-452F-A897-1DE6CE80D10BQ52648399-0DB23543-51E2-419E-B2EF-1897F8637617
P2860
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@ast
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@en
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@nl
type
label
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@ast
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@en
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@nl
prefLabel
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@ast
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@en
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@nl
P2093
P2860
P1476
Prognostic and predictive role ...... ical Trials Group BR.21 trial.
@en
P2093
David P Carbone
Frances A Shepherd
Heinrich Roder
Joanna Roder
Julia Grigorieva
Keyue Ding
Lesley Seymour
P2860
P304
P356
10.1097/JTO.0B013E31826C1155
P577
2012-11-01T00:00:00Z